Face masks supplier United Sewing Automation Inc (USA) revealed on Wednesday that its ASTM Rated Level 3 Disposable PPE face masks produced at its new automated manufacturing facility in Mount Airy, NC is in compliance with the Berry Amendment and qualify for Department of Defense contracts following an extensive testing in an ISO 17025 accredited laboratory in the fight against COVID-9.
The US FDA, which oversees the sale and marketing of all surgical masks, requires that United Sewing must demonstrate mask performance in several critical areas: Bacterial Filtration, Particulate Filtration, Liquid Barrier Protection, Breathability and Flammability.
Based on the FDA requirement, the company's masks passed bacterial filtration efficiency of 99.62%, particulate filtration efficiency of 99.76%, fluid resistance at 160 mmHg, Class 1 flammability of 16CFR 1610, differential pressure at 4.8mm as well as achieved non-cytotoxic and non-irritating biocompatibility.
According to the company, the masks are made from high-quality, USA-sourced materials as well as feature a three-ply design with a built-in adjustable nose bridge and ear loops made of nylon and Spandex, providing a better fit than traditional disposable masks.
Egetis initiates rolling US NDA for Emcitate in MCT8 deficiency
Abbott's Amplatzer Piccolo Delivery System receives US FDA clearance and CE Mark
Amphix Bio announces initial closing of USD12.5m seed financing round
BiBBInstruments reports additional US orders during targeted EndoDrill GI launch
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
Nicox completes key data package for NCX 470 NDA submissions
Immusoft's ISP-002 granted US FDA Orphan Drug Designation in MPS II
Orphan Therapeutics Accelerator signs MoU with Fondazione Telethon
Bioretec wins FDA breakthrough status for biodegradable orthopaedic DrillPin
Amferia raises EUR3.5m to advance antimicrobial wound-care platform
Sobi s Aspaveli marketing authorisation receives positive European regulatory opinion
BioCryst wins FDA approval for oral HAE prophylaxis in young children
NanOlogy launches drug development program for diffuse intrinsic pontine glioma treatment